Prediction of Pregnancy Complications Related to Placental Dysfunction: Protocol for a Prospective Cohort Study (Placental Health Study)
JMIR Research Protocols · 2026-08-25 · 15 · e95231-e95231
DOI: 10.2196/95231 ↗At a glance
Kohortenstudie in JMIR Research Protocols, published online on 2026-08-25. Written by Luhao Han and 12 co-authors. Institution: School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia. Major MEDLINE topics: Pregnancy Complications, Placenta Diseases, Placenta. 64 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Placental dysfunction underlies major obstetric complications, including preeclampsia, fetal growth restriction, preterm birth, and stillbirth. While early identification of pregnancies at high risk of complications enables preventive interventions, current screening methods based on traditional risk factors have limited accuracy.
Objective
This study aims to develop robust prediction models for placental dysfunction–related pregnancy disorders across 3 gestational windows and to determine the optimal delivery time by integrating maternal characteristics, biophysical measurements, and maternal circulating biomarkers.
Methods
The Placental Health Study is a prospective cohort study conducted at the Maternal Fetal Medicine Unit at Gold Coast University Hospital, Australia. Singleton pregnancies are enrolled at 11 to 13 weeks, 26 to 28 weeks, and 35 to 36 weeks of gestation and are followed until delivery. Exclusion criteria are multiple pregnancies, major fetal anomalies, maternal age below 18 years, and inability to provide informed consent. Clinical data, standardized ultrasound and Doppler measurements, hemodynamic parameters, and biospecimens (serum, plasma, whole blood RNA, and urine) are collected at each visit. Three gestational age-specific datasets (11‐13 weeks, 26‐28 weeks, and 35‐36 weeks) will be constructed for model development. Prediction models will be developed using multivariable logistic regression. Competing risks (Fine and Gray) models will be used as sensitivity analyses for outcomes related to gestational age at delivery. Bayesian updating will be applied to refine existing Fetal Medicine Foundation risk estimates using additional biomarkers or variables collected later in pregnancy. Developed models will undergo internal validation via 5-fold cross-validation, with performance assessed through model discrimination, calibration, and comparison against existing approaches. Collected biospecimens will also be analyzed for angiogenic markers and exploratory omics studies.
Results
Recruitment occurred from June 2022 to February 2026, enrolling 1267 participants. As of submission, 1072 (84.6%) participants have completed their pregnancies, 144 (11.4%) participants remain active in follow-up, and 51 (4%) were withdrawn or had missing or duplicated data. Clinical data have undergone preliminary cleaning and descriptive analysis. Biospecimens are being processed for biomarker quantification and exploratory molecular analyses. Two to three publications are anticipated in late 2026 or early 2027.
Conclusions
This cohort establishes a comprehensive database and biospecimen repository to advance prediction of placental dysfunction–related complications. Three-stage recruitment integrated into routine clinical care enhances feasibility and translation potential, enabling dynamic risk assessment and investigation of temporal biomarker changes. Although the single-center design may limit generalizability, warranting future external validation, the interdisciplinary research team brings diverse expertise that strengthens study depth and scope.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia.
- Women-Newborn-Children-Services, Gold Coast University Hospital, Gold Coast, Queensland, Australia.
- Department of Medical Laboratory Science, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
- Maternal Fetal Medicine Unit, Women-Newborn-Children Services, Gold Coast University Hospital, Gold Coast University Hospital, Level 1 B Block, B.1.096, 1 Hospital Boulevard, Gold Coast, Queensland, 4215, Australia, 61…
- School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.
- Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia.
ORCID profiles: Luhao Han, Olivia Holland, Hasini Rathnayake, Cristiane de Freitas Paganoti, Conrado Sávio Ragazini, Elsa Suk Fan Chan, Sally Mahler, Carman Wing Sze Lai, Daniel Lorber Rolnik, Anthony Perkins, David Ellwood, Sailesh Kumar, Fabricio Da Silva Costa
Cite
APA
Han, L., Holland, O., Rathnayake, H., de Freitas Paganoti, C., Ragazini, C. S., Chan, E. S. F., Mahler, S., Lai, C. W. S., Rolnik, D. L., Perkins, A., Ellwood, D., Kumar, S., & Da Silva Costa, F. (2026). Prediction of Pregnancy Complications Related to Placental Dysfunction: Protocol for a Prospective Cohort Study (Placental Health Study). JMIR Research Protocols, 15, e95231-e95231. https://doi.org/10.2196/95231
Vancouver
Han L, Holland O, Rathnayake H, de Freitas Paganoti C, Ragazini CS, Chan ESF, et al. Prediction of Pregnancy Complications Related to Placental Dysfunction: Protocol for a Prospective Cohort Study (Placental Health Study). JMIR Research Protocols. 2026;15:e95231-e95231. doi:10.2196/95231
BibTeX
@article{Han2026,
author = {Han, Luhao and Holland, Olivia and Rathnayake, Hasini and de Freitas Paganoti, Cristiane and Ragazini, Conrado Sávio and Chan, Elsa Suk Fan and Mahler, Sally and Lai, Carman Wing Sze and Rolnik, Daniel Lorber and Perkins, Anthony and Ellwood, David and Kumar, Sailesh and Da Silva Costa, Fabricio},
title = {Prediction of Pregnancy Complications Related to Placental Dysfunction: Protocol for a Prospective Cohort Study (Placental Health Study)},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e95231--e95231},
doi = {10.2196/95231}
}
EUVIMED